查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1930127

全球细胞和基因治疗市场：市场规模、占有率、成长率、行业分析、依类型、应用和地区划分的考虑因素以及未来预测（2026-2034）

Cell and Gene Therapy Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 220 Pages | 商品交期: 请询问到货日

价格

细胞与基因治疗市场的成长因素

受生物技术、基因组学和分子生物学进步的推动，全球细胞和基因治疗市场预计将在未来十年内实现显着增长。根据 Fortune Business Insights 预测，该市场规模预计将在 2025 年达到 131.7 亿美元，并在 2026 年显着增长至 175.4 亿美元，到 2034 年将达到 2005.4 亿美元，预测期内复合年增长率 (CAGR) 为 35.60%。北美地区凭藉其前沿研究、完善的医疗基础设施和强有力的监管支持，在 2025 年将以 40.10% 的市占率引领市场。

细胞和基因疗法专注于为癌症、罕见遗传疾病和神经系统疾病等难治性疾病提供个人化治疗。这些疗法透过纠正或替换缺陷细胞或基因，提供长期且可能治癒的疗效。产业领导者之间的合作正在加速产品开发，拜耳公司和葛兰素史克公司等企业正大力投资研发，以拓展其治疗产品线。例如，2024年9月，Evotec SE与诺和诺德公司合作，开始开发现成的细胞疗法产品，体现了对创新和全球合作的重视。

市场动态

驱动因素

癌症和罕见遗传疾病的日益普及是推动市场发展的主要因素。细胞和基因疗法能够纠正基因突变或恢復治疗选择有限的患者的细胞功能。基因组学研究和个人化医疗的进步进一步促进了标靶疗法的开发。 根据世界卫生组织（2025年8月）的数据，截至2021年，全球约有774万人患有镰状细胞贫血症，凸显了创新疗法的紧迫性。

抑制剂

生产流程复杂且成本高昂限制了其广泛应用。个人化治疗需要复杂的生产流程、专门的临床试验和严格的品质控制，这增加了成本并降低了可扩展性。例如，用于治疗视力丧失的基因治疗药物Luxturna价格昂贵，每隻眼睛的费用约为42.5万美元，这给患者和医疗保健系统都造成了经济负担。

机会

开发治疗阿兹海默症、帕金森氏症和肌萎缩侧索硬化症（ALS）等神经退化性疾病的新疗法具有巨大的成长潜力。各公司正在利用基因编辑技术来解决疾病的根本原因。 2025年1月，拜耳公司和BlueRock Therapeutics LP启动了VemdaneProcel的III期临床试验，VemdaneProcel是一种用于治疗帕金森氏症的研细胞疗法，这标誌着神经退化性疾病治疗领域迎来了变革性的机会。

挑战

目前，开发和生产疗法所需的专业人才——科学家、临床医生和技术人员——严重短缺。根据国际细胞与基因治疗学会（ISCT，2025年9月）的数据，只有35%的技术职缺人员配备充足，显示人才短缺可能会阻碍产业发展。

市场趋势

一个关键趋势是基于CRISPR技术的精准医疗日益受到关注。 CRISPR技术能够实现精准的基因编辑，进而提高遗传疾病治疗的疗效和安全性。 2024 年 5 月，由美国国立卫生研究院 (NIH) 资助的研究人员开发出一种基于 CRISPR 技术的氨甲酰磷酸合成酶 1 (CPS1) 缺乏症疗法，证明了该技术在罕见遗传疾病领域的广泛应用前景。

市场区隔分析

依类型

  • 在标靶癌症疗法和监管审批不断增加的推动下，细胞疗法在 2026 年占市场主导地位，市占率高达 70.35%。例如，T 细胞受体疗法 Tessela 于 2024 年 8 月获得 FDA 批准，用于治疗转移性滑膜肉瘤。
  • 在 2024 年，基因疗法占第二大市场占有率，其产品类型、载体类型和适应症各不相同。

依最终使用者划分

  • 预计到 2026 年，医院和诊所将以 55.59% 的市场占有率引领市场，因为这些专业治疗需要熟练的管理，并且通常是合作开发项目的一部分。
  • 预计专科诊所的复合年增长率将达到 36.99%，反映出其服务可近性和普及率的提高。

区域展望

  • 北美：在先进的研究和医疗保健基础设施的支持下，预计该市场在 2025 年将达到 52.7 亿美元，在 2026 年将达到 70 亿美元。光是美国在 2026 年就占了 65.2 亿美元。
  • 欧洲：预计该市场在 2026 年将达到 61.5 亿美元，其中英国、德国和法国的市场规模分别为 10 亿美元、15 亿美元和 7.9 亿美元。
  • 亚太地区：预计2026年将达到26.7亿美元，其中印度和中国的市场规模分别为2.2亿美元和9.6亿美元。
  • 拉丁美洲：到 2026 年将达到 11.2 亿美元。
  • 中东和非洲（海湾合作委员会）：到 2025 年将达到 2.6 亿美元。

目录

第一章：引言

第二章：摘要整理

第三章：市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机遇
  • 市场趋势

第四章：关键考虑因素

  • 针对新疾病适应症的细胞和基因疗法开发
  • 主要国家的监管情况
  • 市场技术进步
  • 新产品主要公司产品发布
  • 主要公司产品线分析
  • 关键产业趋势：併购、业务合作、产品发布等
  • 市场格局：定价与报销趋势
  • 製造与供应链洞察
  • 市场投资与融资趋势
  • 概述：患者获得治疗的机会与伦理考量

第五章 全球细胞与基因治疗市场分析：洞察与预测（2021-2034）

  • 市场分析、洞察与预测：依类型划分
    • 细胞疗法
      • 疗法类型
      • 产品类型
      • 适应症
    • 基因疗法
      • 产品类型
      • 载体类型
      • 适应症
  • 市场分析、洞察与预测：依最终用户划分
    • 医院和诊所
    • 专科诊所
    • 其他
  • 市场分析、洞察与预测：依地区划分
    • 北美
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第六章 北美细胞与基因治疗市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 美国
    • 加拿大

第七章 欧洲细胞与基因治疗市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 斯堪的纳维亚
    • 其他欧洲国家

第八章 亚太地区细胞与基因治疗市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 中国
    • 日本
    • 印度
    • 澳大利亚
    • 东南亚
    • 亚太其他地区

第九章 拉丁美洲细胞与基因治疗市场分析：洞察与预测（2021-2034）

  • 依国家/地区
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区

第十章：中东与非洲细胞与基因治疗市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 海湾合作委员会 (GCC) 国家
    • 南非
    • 中东和非洲其他地区

第十一章 竞争分析

  • 全球市占率分析（2025）
  • 公司简介
  • Vertex Pharmaceuticals Incorporated
  • Krystal Biotech, Inc.
  • Rocket Pharmaceuticals
  • CRISPR Therapeutics
  • Bayer AG
  • Novartis AG
  • Gilead Sciences, Inc.
  • F. Hoffmann-La Roche Ltd(Spark Therapeutics)
  • Bristol-Myers Squibb Company
  • Adaptimmune
Product Code: FBI114130

Growth Factors of cell and gene therapy Market

The global cell and gene therapy market is poised for exceptional growth in the coming decade, driven by advancements in biotechnology, genomics, and molecular biology. According to Fortune Business Insights, the market was valued at USD 13.17 billion in 2025, with projections indicating growth to USD 17.54 billion in 2026 and a remarkable surge to USD 200.54 billion by 2034, reflecting a CAGR of 35.60% during the forecast period. In 2025, North America dominated the market with a 40.10% share, driven by cutting-edge research, established healthcare infrastructure, and strong regulatory support.

Cell and gene therapy focuses on personalized treatments for non-drug treatable diseases, including cancers, rare genetic disorders, and neurological conditions. These therapies involve modifying or replacing defective cells and genes, offering long-term and potentially curative benefits. Collaborations among industry leaders are accelerating product development, with companies such as Bayer AG and GSK plc investing heavily in R&D to expand their pipeline of therapies. For instance, in September 2024, Evotec SE partnered with Novo Nordisk A/s to develop off-the-shelf cell therapy products, highlighting the emphasis on innovation and global collaboration.

Market Dynamics

Drivers

The rising prevalence of cancer and rare genetic disorders is a major market driver. Cell and gene therapies correct genetic mutations or restore cell function in patients with limited treatment options. Advancements in genomic research and personalized medicine further enhance the development of targeted therapies. As per the World Health Organization (August 2025), approximately 7.74 million people globally were living with sickle cell disease in 2021, emphasizing the urgent need for innovative therapies.

Restraints

High manufacturing complexities and costs limit adoption. Personalized therapies require intricate production processes, specialized clinical studies, and rigorous quality control, which increase costs and reduce scalability. For example, Luxturna, a gene therapy for vision loss, costs approximately USD 425,000 per eye, creating financial barriers for patients and healthcare systems.

Opportunities

The development of new therapies for neurodegenerative disorders such as Alzheimer's, Parkinson's, and ALS represents significant growth potential. Companies are leveraging gene editing techniques to address underlying disease causes. In January 2025, Bayer AG and BlueRock Therapeutics LP initiated the bemdaneprocel Phase III trial, an investigational cell therapy for Parkinson's disease, signaling transformative opportunities in neurodegenerative treatment.

Challenges

The market faces a shortage of skilled professionals, including scientists, clinicians, and technical staff, required to develop and manufacture therapies. As per the International Society for Cell & Gene Therapy (ISCT, September 2025), only 35% of technical positions were adequately staffed, indicating a workforce gap that may impede growth.

Market Trends

A key trend is the increasing focus on CRISPR-based precision medicine. CRISPR enables precise gene editing, improving therapy efficacy and safety for genetic disorders. In May 2024, NIH-supported researchers developed a CRISPR-based therapy for carbamoyl phosphate synthetase 1 (CPS1) deficiency, demonstrating the technology's versatility for rare genetic diseases.

Segmentation Analysis

By Type

  • Cell therapy dominated the market in 2026 with a 70.35% share, driven by targeted therapies for cancers and increased regulatory approvals. For example, Tecelra, a T-cell receptor therapy, received FDA approval in August 2024 for metastatic synovial sarcoma.
  • Gene therapy held the second-leading share in 2024, focusing on various product types, vector types, and indications.

By End User

  • Hospitals & clinics led with a 55.59% share in 2026, as these specialized therapies require skilled administration and are often part of collaborative development programs.
  • Specialty clinics are projected to grow at a CAGR of 36.99%, reflecting increased access and adoption.

Regional Outlook

  • North America: USD 5.27 billion in 2025, USD 7 billion in 2026, driven by advanced research and healthcare infrastructure; the U.S. accounted for USD 6.52 billion in 2026.
  • Europe: Expected to reach USD 6.15 billion in 2026, with the U.K., Germany, and France valued at USD 1 billion, USD 1.5 billion, and USD 0.79 billion, respectively.
  • Asia Pacific: Projected at USD 2.67 billion in 2026, with India and China at USD 0.22 billion and USD 0.96 billion.
  • Latin America: USD 1.12 billion in 2026.
  • Middle East & Africa (GCC): USD 0.26 billion in 2025.

Competitive Landscape

The market is consolidated, dominated by Novartis AG, Gilead Sciences, Inc., and Bayer AG, offering diverse CGT products and expanding globally through R&D and strategic collaborations. Other major players include Rocket Pharmaceuticals, Bristol-Myers Squibb, Krystal Biotech, Vertex Pharmaceuticals, and CRISPR Therapeutics. Key developments include FDA approvals for advanced therapies, new CAR-T cell therapies, and partnerships to strengthen onshore manufacturing.

Conclusion

The global cell and gene therapy market is projected to grow from USD 13.17 billion in 2025 to USD 200.54 billion by 2034, reflecting rapid adoption of targeted, personalized therapies for cancer, genetic, and neurodegenerative diseases. Despite challenges such as high costs and skilled workforce shortages, innovations in CRISPR-based therapies, cell engineering, and collaborative R&D are expected to drive unprecedented market expansion.

Segmentation By Type

  • Cell Therapy
    • Therapy Type
  • CAR-T Cell Therapy
  • TCR-T Cell Therapy
  • Natural Killer (NK) Cells
  • Others
    • Product Type
  • Kymriah
  • Yescarta
  • Tecartus
  • Breyanzi
  • Abecma
  • Carvykti
  • Others
    • Indication
  • Oncology
  • Others
  • Gene Therapy
    • Product Type
  • Zolgensma
  • Luxturna
  • Roctavian
  • Others
    • Vector Type
  • Viral Vectors
  • Non-Viral Vectors
    • Indication
  • Genetic Disorders
  • Ophthalmology
  • Hematology
  • Others

By End User

  • Hospitals & Clinics
  • Specialty Clinics
  • Others

By Geography

  • North America (By Type, End User, and Country)
    • U.S.
    • Canada
  • Europe (By Type, End User, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Type, End User, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Type, End User, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Type, End User, and Country/Sub-region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Development of Cell and Gene Therapy for New Disease Indications
  • 4.2. Regulatory Scenarios, By Key Countries/Regions
  • 4.3. Technological Advancements in the Market
  • 4.4. New Product Launches, By Key Players
  • 4.5. Pipeline Analysis, By Key Companies
  • 4.6. Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, and Others)
  • 4.7. Pricing & Reimbursement Landscape in the Market
  • 4.8. Manufacturing & Supply Chain Insights
  • 4.9. Investment & Funding Trends in the Market
  • 4.10. Overview: Patient Access to the Therapy & Ethical Considerations

5. Global Cell and Gene Therapy Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Type
    • 5.1.1. Cell Therapy
      • 5.1.1.1. Therapy Type
        • 5.1.1.1.1. CAR-T Cell Therapy
        • 5.1.1.1.2. TCR-T Cell Therapy
        • 5.1.1.1.3. Natural Killer (NK) Cells
        • 5.1.1.1.4. Others
      • 5.1.1.2. Product Type
        • 5.1.1.2.1. Kymriah
        • 5.1.1.2.2. Yescarta
        • 5.1.1.2.3. Tecartus
        • 5.1.1.2.4. Breyanzi
        • 5.1.1.2.5. Abecma
        • 5.1.1.2.6. Carvykti
        • 5.1.1.2.7. Others
      • 5.1.1.3. Indication
        • 5.1.1.3.1. Oncology
        • 5.1.1.3.2. Others
    • 5.1.2. Gene Therapy
      • 5.1.2.1. Product Type
        • 5.1.2.1.1. Zolgensma
        • 5.1.2.1.2. Luxturna
        • 5.1.2.1.3. Roctavian
        • 5.1.2.1.4. Others
      • 5.1.2.2. Vector Type
        • 5.1.2.2.1. Viral Vectors
        • 5.1.2.2.2. Non-Viral Vectors
      • 5.1.2.3. Indication
        • 5.1.2.3.1. Genetic Disorders
        • 5.1.2.3.2. Ophthalmology
        • 5.1.2.3.3. Hematology
        • 5.1.2.3.4. Others
  • 5.2. Market Analysis, Insights and Forecast - By End User
    • 5.2.1. Hospitals & Clinics
    • 5.2.2. Specialty Clinics
    • 5.2.3. Others
  • 5.3. Market Analysis, Insights and Forecast - Region
    • 5.3.1. North America
    • 5.3.2. Europe
    • 5.3.3. Asia Pacific
    • 5.3.4. Latin America
    • 5.3.5. Middle East & Africa

6. North America Cell and Gene Therapy Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Type
    • 6.1.1. Cell Therapy
      • 6.1.1.1. Therapy Type
        • 6.1.1.1.1. CAR-T Cell Therapy
        • 6.1.1.1.2. TCR-T Cell Therapy
        • 6.1.1.1.3. Natural Killer (NK) Cells
        • 6.1.1.1.4. Others
      • 6.1.1.2. Product Type
        • 6.1.1.2.1. Kymriah
        • 6.1.1.2.2. Yescarta
        • 6.1.1.2.3. Tecartus
        • 6.1.1.2.4. Breyanzi
        • 6.1.1.2.5. Abecma
        • 6.1.1.2.6. Carvykti
        • 6.1.1.2.7. Others
      • 6.1.1.3. Indication
        • 6.1.1.3.1. Oncology
        • 6.1.1.3.2. Others
    • 6.1.2. Gene Therapy
      • 6.1.2.1. Product Type
        • 6.1.2.1.1. Zolgensma
        • 6.1.2.1.2. Luxturna
        • 6.1.2.1.3. Roctavian
        • 6.1.2.1.4. Others
      • 6.1.2.2. Vector Type
        • 6.1.2.2.1. Viral Vectors
        • 6.1.2.2.2. Non-Viral Vectors
      • 6.1.2.3. Indication
        • 6.1.2.3.1. Genetic Disorders
        • 6.1.2.3.2. Ophthalmology
        • 6.1.2.3.3. Hematology
        • 6.1.2.3.4. Others
  • 6.2. Market Analysis, Insights and Forecast - By End User
    • 6.2.1. Hospitals & Clinics
    • 6.2.2. Specialty Clinics
    • 6.2.3. Others
  • 6.3. Market Analysis, Insights and Forecast - By Country
    • 6.3.1. U.S.
    • 6.3.2. Canada

7. Europe Cell and Gene Therapy Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Type
    • 7.1.1. Cell Therapy
      • 7.1.1.1. Therapy Type
        • 7.1.1.1.1. CAR-T Cell Therapy
        • 7.1.1.1.2. TCR-T Cell Therapy
        • 7.1.1.1.3. Natural Killer (NK) Cells
        • 7.1.1.1.4. Others
      • 7.1.1.2. Product Type
        • 7.1.1.2.1. Kymriah
        • 7.1.1.2.2. Yescarta
        • 7.1.1.2.3. Tecartus
        • 7.1.1.2.4. Breyanzi
        • 7.1.1.2.5. Abecma
        • 7.1.1.2.6. Carvykti
        • 7.1.1.2.7. Others
      • 7.1.1.3. Indication
        • 7.1.1.3.1. Oncology
        • 7.1.1.3.2. Others
    • 7.1.2. Gene Therapy
      • 7.1.2.1. Product Type
        • 7.1.2.1.1. Zolgensma
        • 7.1.2.1.2. Luxturna
        • 7.1.2.1.3. Roctavian
        • 7.1.2.1.4. Others
      • 7.1.2.2. Vector Type
        • 7.1.2.2.1. Viral Vectors
        • 7.1.2.2.2. Non-Viral Vectors
      • 7.1.2.3. Indication
        • 7.1.2.3.1. Genetic Disorders
        • 7.1.2.3.2. Ophthalmology
        • 7.1.2.3.3. Hematology
        • 7.1.2.3.4. Others
  • 7.2. Market Analysis, Insights and Forecast - By End User
    • 7.2.1. Hospitals & Clinics
    • 7.2.2. Specialty Clinics
    • 7.2.3. Others
  • 7.3. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.3.1. Germany
    • 7.3.2. U.K.
    • 7.3.3. France
    • 7.3.4. Italy
    • 7.3.5. Spain
    • 7.3.6. Scandinavia
    • 7.3.7. Rest of Europe

8. Asia Pacific Cell and Gene Therapy Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Type
    • 8.1.1. Cell Therapy
      • 8.1.1.1. Therapy Type
        • 8.1.1.1.1. CAR-T Cell Therapy
        • 8.1.1.1.2. TCR-T Cell Therapy
        • 8.1.1.1.3. Natural Killer (NK) Cells
        • 8.1.1.1.4. Others
      • 8.1.1.2. Product Type
        • 8.1.1.2.1. Kymriah
        • 8.1.1.2.2. Yescarta
        • 8.1.1.2.3. Tecartus
        • 8.1.1.2.4. Breyanzi
        • 8.1.1.2.5. Abecma
        • 8.1.1.2.6. Carvykti
        • 8.1.1.2.7. Others
      • 8.1.1.3. Indication
        • 8.1.1.3.1. Oncology
        • 8.1.1.3.2. Others
    • 8.1.2. Gene Therapy
      • 8.1.2.1. Product Type
        • 8.1.2.1.1. Zolgensma
        • 8.1.2.1.2. Luxturna
        • 8.1.2.1.3. Roctavian
        • 8.1.2.1.4. Others
      • 8.1.2.2. Vector Type
        • 8.1.2.2.1. Viral Vectors
        • 8.1.2.2.2. Non-Viral Vectors
      • 8.1.2.3. Indication
        • 8.1.2.3.1. Genetic Disorders
        • 8.1.2.3.2. Ophthalmology
        • 8.1.2.3.3. Hematology
        • 8.1.2.3.4. Others
  • 8.2. Market Analysis, Insights and Forecast - By End User
    • 8.2.1. Hospitals & Clinics
    • 8.2.2. Specialty Clinics
    • 8.2.3. Others
  • 8.3. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.3.1. China
    • 8.3.2. Japan
    • 8.3.3. India
    • 8.3.4. Australia
    • 8.3.5. Southeast Asia
    • 8.3.6. Rest of Asia Pacific

9. Latin America Cell and Gene Therapy Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Type
    • 9.1.1. Cell Therapy
      • 9.1.1.1. Therapy Type
        • 9.1.1.1.1. CAR-T Cell Therapy
        • 9.1.1.1.2. TCR-T Cell Therapy
        • 9.1.1.1.3. Natural Killer (NK) Cells
        • 9.1.1.1.4. Others
      • 9.1.1.2. Product Type
        • 9.1.1.2.1. Kymriah
        • 9.1.1.2.2. Yescarta
        • 9.1.1.2.3. Tecartus
        • 9.1.1.2.4. Breyanzi
        • 9.1.1.2.5. Abecma
        • 9.1.1.2.6. Carvykti
        • 9.1.1.2.7. Others
      • 9.1.1.3. Indication
        • 9.1.1.3.1. Oncology
        • 9.1.1.3.2. Others
    • 9.1.2. Gene Therapy
      • 9.1.2.1. Product Type
        • 9.1.2.1.1. Zolgensma
        • 9.1.2.1.2. Luxturna
        • 9.1.2.1.3. Roctavian
        • 9.1.2.1.4. Others
      • 9.1.2.2. Vector Type
        • 9.1.2.2.1. Viral Vectors
        • 9.1.2.2.2. Non-Viral Vectors
      • 9.1.2.3. Indication
        • 9.1.2.3.1. Genetic Disorders
        • 9.1.2.3.2. Ophthalmology
        • 9.1.2.3.3. Hematology
        • 9.1.2.3.4. Others
  • 9.2. Market Analysis, Insights and Forecast - By End User
    • 9.2.1. Hospitals & Clinics
    • 9.2.2. Specialty Clinics
    • 9.2.3. Others
  • 9.3. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.3.1. Brazil
    • 9.3.2. Mexico
    • 9.3.3. Rest of Latin America

10. Middle East & Africa Cell and Gene Therapy Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Type
    • 10.1.1. Cell Therapy
      • 10.1.1.1. Therapy Type
        • 10.1.1.1.1. CAR-T Cell Therapy
        • 10.1.1.1.2. TCR-T Cell Therapy
        • 10.1.1.1.3. Natural Killer (NK) Cells
        • 10.1.1.1.4. Others
      • 10.1.1.2. Product Type
        • 10.1.1.2.1. Kymriah
        • 10.1.1.2.2. Yescarta
        • 10.1.1.2.3. Tecartus
        • 10.1.1.2.4. Breyanzi
        • 10.1.1.2.5. Abecma
        • 10.1.1.2.6. Carvykti
        • 10.1.1.2.7. Others
      • 10.1.1.3. Indication
        • 10.1.1.3.1. Oncology
        • 10.1.1.3.2. Others
    • 10.1.2. Gene Therapy
      • 10.1.2.1. Product Type
        • 10.1.2.1.1. Zolgensma
        • 10.1.2.1.2. Luxturna
        • 10.1.2.1.3. Roctavian
        • 10.1.2.1.4. Others
      • 10.1.2.2. Vector Type
        • 10.1.2.2.1. Viral Vectors
        • 10.1.2.2.2. Non-Viral Vectors
      • 10.1.2.3. Indication
        • 10.1.2.3.1. Genetic Disorders
        • 10.1.2.3.2. Ophthalmology
        • 10.1.2.3.3. Hematology
        • 10.1.2.3.4. Others
  • 10.2. Market Analysis, Insights and Forecast - By End User
    • 10.2.1. Hospitals & Clinics
    • 10.2.2. Specialty Clinics
    • 10.2.3. Others
  • 10.3. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.3.1. GCC
    • 10.3.2. South Africa
    • 10.3.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles (Overview, Products, SWOT analysis, Recent developments, strategies, financials (based on availability))
    • 11.2.1. Vertex Pharmaceuticals Incorporated
    • 11.2.2. Krystal Biotech, Inc.
    • 11.2.3. Rocket Pharmaceuticals
    • 11.2.4. CRISPR Therapeutics
    • 11.2.5. Bayer AG
    • 11.2.6. Novartis AG
    • 11.2.7. Gilead Sciences, Inc.
    • 11.2.8. F. Hoffmann-La Roche Ltd (Spark Therapeutics)
    • 11.2.9. Bristol-Myers Squibb Company
    • 11.2.10. Adaptimmune

List of Tables

  • Table 1: Global Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Type, 2021-2034
  • Table 2: Global Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Therapy Type, 2021-2034
  • Table 3: Global Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Product Type, 2021-2034
  • Table 4: Global Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Indication, 2021-2034
  • Table 5: Global Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Product Type, 2021-2034
  • Table 6: Global Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Vector Type, 2021-2034
  • Table 7: Global Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Indication, 2021-2034
  • Table 8: Global Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by End User 2021-2034
  • Table 9: Global Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Region, 2021-2034
  • Table 10: North America Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Type, 2021-2034
  • Table 11: North America Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Therapy Type, 2021-2034
  • Table 12: North America Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Product Type, 2021-2034
  • Table 13: North America Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Indication, 2021-2034
  • Table 14: North America Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Product Type, 2021-2034
  • Table 15: North America Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Vector Type, 2021-2034
  • Table 16: North America Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Indication, 2021-2034
  • Table 17: North America Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by End User 2021-2034
  • Table 18: North America Cell and Gene Therapy Market Revenue (USD Billion) Forecast, By Country, 2021-2034
  • Table 19: Europe Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Type, 2021-2034
  • Table 20: Europe Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Therapy Type, 2021-2034
  • Table 21: Europe Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Product Type, 2021-2034
  • Table 22: Europe Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Indication, 2021-2034
  • Table 23: Europe Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Product Type, 2021-2034
  • Table 24: Europe Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Vector Type, 2021-2034
  • Table 25: Europe Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Indication, 2021-2034
  • Table 26: Europe Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by End User 2021-2034
  • Table 27: Europe Cell and Gene Therapy Market Revenue (USD Billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 28: Asia Pacific Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Type, 2021-2034
  • Table 29: Asia Pacific Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Therapy Type, 2021-2034
  • Table 30: Asia Pacific Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Product Type, 2021-2034
  • Table 31: Asia Pacific Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Indication, 2021-2034
  • Table 32: Asia Pacific Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Product Type, 2021-2034
  • Table 33: Asia Pacific Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Vector Type, 2021-2034
  • Table 34: Asia Pacific Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Indication, 2021-2034
  • Table 35: Asia Pacific Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by End User 2021-2034
  • Table 36: Asia Pacific Cell and Gene Therapy Market Revenue (USD Billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 37: Latin America Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Type, 2021-2034
  • Table 38: Latin America Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Therapy Type, 2021-2034
  • Table 39: Latin America Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Product Type, 2021-2034
  • Table 40: Latin America Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Indication, 2021-2034
  • Table 41: Latin America Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Product Type, 2021-2034
  • Table 42: Latin America Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Vector Type, 2021-2034
  • Table 43: Latin America Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Indication, 2021-2034
  • Table 44: Latin America Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by End User 2021-2034
  • Table 45: Latin America Cell and Gene Therapy Market Revenue (USD Billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 46: Middle East & Africa Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Type, 2021-2034
  • Table 47: Middle East & Africa Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Therapy Type, 2021-2034
  • Table 48: Middle East & Africa Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Product Type, 2021-2034
  • Table 49: Middle East & Africa Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Indication, 2021-2034
  • Table 50: Middle East & Africa Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Product Type, 2021-2034
  • Table 51: Middle East & Africa Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Vector Type, 2021-2034
  • Table 52: Middle East & Africa Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Indication, 2021-2034
  • Table 53: Middle East & Africa Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by End User 2021-2034
  • Table 54: Middle East & Africa Cell and Gene Therapy Market Revenue (USD Billion) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Cell and Gene Therapy Market Revenue Breakdown (USD Billion, %) by Region, 2025 & 2034
  • Figure 2: Global Cell and Gene Therapy Market Value Share (%), by Type, 2025 & 2034
  • Figure 3: Global Cell and Gene Therapy Market Value Share (%), by End User, 2025 & 2034
  • Figure 4: Global Cell and Gene Therapy Market Value (USD Billion), by Region, 2025 & 2034
  • Figure 5: North America Cell and Gene Therapy Market Value (USD Billion), by Type, 2025 & 2034
  • Figure 6: North America Cell and Gene Therapy Market Value Share (%), by Type, 2025
  • Figure 7: North America Cell and Gene Therapy Market Value (USD Billion), by End User, 2025 & 2034
  • Figure 8: North America Cell and Gene Therapy Market Value Share (%), by End User, 2025
  • Figure 9: North America Cell and Gene Therapy Market Value (USD Billion), By Country, 2025 & 2034
  • Figure 10: North America Cell and Gene Therapy Market Value Share (%), By Country, 2025
  • Figure 11: Europe Cell and Gene Therapy Market Value (USD Billion), by Type, 2025 & 2034
  • Figure 12: Europe Cell and Gene Therapy Market Value Share (%), by Type, 2025
  • Figure 13: Europe Cell and Gene Therapy Market Value (USD Billion), by End User, 2025 & 2034
  • Figure 14: Europe Cell and Gene Therapy Market Value Share (%), by End User, 2025
  • Figure 15: Europe Cell and Gene Therapy Market Value (USD Billion), By Country/ Sub-region, 2025 & 2034
  • Figure 16: Europe Cell and Gene Therapy Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 17: Asia Pacific Cell and Gene Therapy Market Value (USD Billion), by Type, 2025 & 2034
  • Figure 18: Asia Pacific Cell and Gene Therapy Market Value Share (%), by Type, 2025
  • Figure 19: Asia Pacific Cell and Gene Therapy Market Value (USD Billion), by End User, 2025 & 2034
  • Figure 20: Asia Pacific Cell and Gene Therapy Market Value Share (%), by End User, 2025
  • Figure 21: Asia Pacific Cell and Gene Therapy Market Value (USD Billion), By Country/ Sub-region, 2025 & 2034
  • Figure 22: Asia Pacific Cell and Gene Therapy Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 23: Latin America Cell and Gene Therapy Market Value (USD Billion), by Type, 2025 & 2034
  • Figure 24: Latin America Cell and Gene Therapy Market Value Share (%), by Type, 2025
  • Figure 25: Latin America Cell and Gene Therapy Market Value (USD Billion), by End User, 2025 & 2034
  • Figure 26: Latin America Cell and Gene Therapy Market Value Share (%), by End User, 2025
  • Figure 27: Latin America Cell and Gene Therapy Market Value (USD Billion), By Country/ Sub-region, 2025 & 2034
  • Figure 28: Latin America Cell and Gene Therapy Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 29: Middle East & Africa Cell and Gene Therapy Market Value (USD Billion), by Type, 2025 & 2034
  • Figure 30: Middle East & Africa Cell and Gene Therapy Market Value Share (%), by Type, 2025
  • Figure 31: Middle East & Africa Cell and Gene Therapy Market Value (USD Billion), by End User, 2025 & 2034
  • Figure 32: Middle East & Africa Cell and Gene Therapy Market Value Share (%), by End User, 2025
  • Figure 33: Middle East & Africa Cell and Gene Therapy Market Value (USD Billion), By Country/ Sub-region, 2025 & 2034
  • Figure 34: Middle East & Africa Cell and Gene Therapy Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 35: Global Cell and Gene Therapy Market Share (%), By Company, 2025